HK1246367A1 - 转移性疾病的基因标记预测 - Google Patents

转移性疾病的基因标记预测 Download PDF

Info

Publication number
HK1246367A1
HK1246367A1 HK18105968.7A HK18105968A HK1246367A1 HK 1246367 A1 HK1246367 A1 HK 1246367A1 HK 18105968 A HK18105968 A HK 18105968A HK 1246367 A1 HK1246367 A1 HK 1246367A1
Authority
HK
Hong Kong
Prior art keywords
metastatic disease
gene signatures
signatures predictive
expression level
cancer
Prior art date
Application number
HK18105968.7A
Other languages
English (en)
Chinese (zh)
Inventor
Steven Walker
Laura Hill
Andrena MCCAVIGAN
Sinead DONEGAN
Timothy Davison
Richard Kennedy
Denis Paul Harkin
Bethanie PRICE
Original Assignee
Almac Diagnostic Services Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostic Services Limited filed Critical Almac Diagnostic Services Limited
Publication of HK1246367A1 publication Critical patent/HK1246367A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18105968.7A 2015-06-17 2016-06-17 转移性疾病的基因标记预测 HK1246367A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1510684.2A GB201510684D0 (en) 2015-06-17 2015-06-17 Gene signatures predictive of metastatic disease
GB201510684 2015-06-17
PCT/GB2016/051825 WO2016203262A2 (en) 2015-06-17 2016-06-17 Gene signatures predictive of metastatic disease

Publications (1)

Publication Number Publication Date
HK1246367A1 true HK1246367A1 (zh) 2018-09-07

Family

ID=53784091

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105968.7A HK1246367A1 (zh) 2015-06-17 2016-06-17 转移性疾病的基因标记预测

Country Status (8)

Country Link
US (1) US20210254166A1 (https=)
EP (1) EP3310927B1 (https=)
JP (1) JP2018527886A (https=)
CN (1) CN108513587A (https=)
CA (1) CA2989388A1 (https=)
GB (1) GB201510684D0 (https=)
HK (1) HK1246367A1 (https=)
WO (1) WO2016203262A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11341138B2 (en) * 2017-12-06 2022-05-24 International Business Machines Corporation Method and system for query performance prediction
GB201901439D0 (en) * 2019-02-01 2019-03-27 Univ London Method of predicting survival rates for cancer patients
GB201903014D0 (en) * 2019-03-06 2019-04-17 Univ Edinburgh Macrophage markers in cancer
GB201903015D0 (en) * 2019-03-08 2019-04-17 Univ Edinburgh Macrophage expression in breast cancer
US20210225460A1 (en) * 2020-01-21 2021-07-22 Genialis Inc. Evaluating the robustness and transferability of predictive signatures across molecular biomarker datasets
CA3174199A1 (en) 2020-04-09 2021-10-14 Ashraf Hafez Predicting likelihood and site of metastasis from patient records
BR112022024206A2 (pt) 2020-06-29 2023-01-03 Ionis Pharmaceuticals Inc Compostos e métodos para modular plp1
WO2022086914A1 (en) * 2020-10-19 2022-04-28 Temple University - Of The Commonwealth System Of Higher Education Genetic approach to suppress coronaviruses
CN120197220B (zh) * 2025-05-23 2025-08-01 华信咨询设计研究院有限公司 一种基于数据集中度的数据风险评估方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4437975A (en) 1977-07-20 1984-03-20 Mobil Oil Corporation Manufacture of lube base stock oil
CA1340843C (en) 1987-07-31 1999-12-07 J. Lawrence Burg Selective amplification of target polynucleotide sequences
CA2005589C (en) 1988-12-16 2001-02-06 Akzo Nobel Nv Self-sustained, sequence replication system
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
AU2002215345A1 (en) * 2000-10-13 2002-04-22 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
WO2004067726A2 (en) 2003-01-29 2004-08-12 Keck Graduate Institute Isothermal reactions for the amplification of oligonucleotides
CA2519630A1 (en) * 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
US7306910B2 (en) * 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
EP1815021A2 (en) 2004-11-03 2007-08-08 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
US20140018249A1 (en) * 2006-07-26 2014-01-16 Health Discovery Corporation Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
US20090082218A1 (en) 2007-08-13 2009-03-26 Paul Harkin 3'-Based sequencing approach for microarray manufacture
ES2704645T3 (es) * 2008-12-11 2019-03-19 Univ California Membrana de filtración
US20120245235A1 (en) * 2009-12-01 2012-09-27 Compenda Bioscience, Inc Classification of cancers
CA2836277A1 (en) * 2011-05-17 2012-11-22 Takeda Pharmaceutical Company Limited Pharmaceutical compositions and methods for treating cancer
CA2879557A1 (en) * 2012-07-20 2014-01-23 Diagnocure Inc. Methods, kits and compositions for providing a clinical assessment of prostate cancer

Also Published As

Publication number Publication date
JP2018527886A (ja) 2018-09-27
CA2989388A1 (en) 2016-12-22
GB201510684D0 (en) 2015-08-05
CN108513587A (zh) 2018-09-07
EP3310927B1 (en) 2021-05-19
EP3310927A2 (en) 2018-04-25
US20210254166A1 (en) 2021-08-19
WO2016203262A2 (en) 2016-12-22
WO2016203262A3 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
HK1246367A1 (zh) 转移性疾病的基因标记预测
SG10201908277TA (en) Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
BR112017012222A2 (pt) métodos para derivar um biomarcador de assinatura gênica e para tratar um paciente que tem um tumor, método e sistema para testar uma amostra de tumor removida de um paciente, e, kit.
BR112017025254A2 (pt) ?métodos para detecção de pelo menos uma mutação em uma pluralidade de genes relacionados ao câncer, selecionar um indivíduo para tratamento e prever a probabilidade de capacidade de resposta ao tratamento?
WO2014144121A3 (en) Classification and actionability indices for lung cancer
MA39963A (fr) Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
WO2013182912A3 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
BR112016006635A2 (pt) método de seleção dentre uma pluralidade de planos de tratamento para tratar um tumor, e, produto de computador
WO2016048833A3 (en) Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
BR112017007962A2 (pt) método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit
WO2014140933A3 (en) Method for the prognosis and treatment of cancer metastasis
WO2018007872A9 (en) Biomarkers for inflammatory bowel disease
Cerulli The impact of technological capabilities on invention: An investigation based on country responsiveness scores
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
WO2014022826A3 (en) Biomarker associated with risk of melanoma reoccurrence
EP4524569A3 (en) Methods, compositions and devices for treating cancer with illudofulvenes
WO2014145751A3 (en) Targeted therapies for cancer
EP3495502A3 (en) Biomarkers for premature birth
EA201890649A1 (ru) Новые биомаркеры и способы лечения рака
BR112015022977A2 (pt) métodos para predição de risco de metástase em melanoma cutâneo
EA201692497A1 (ru) Биомаркеры ответа на ингибиторы ezh2
WO2018046770A3 (en) Marker and target as a diagnostic variable and target for therapy of metastatic cancer
Ghosh et al. Selection of genes mediating certain cancers, using a neuro-fuzzy approach
WO2016034715A3 (fr) Methode de prediction de l'evolution clinique du cancer colorectal
EP3444362A3 (en) Circulating mirnas as early detection marker and prognostic marker